New drug trial aims to tame severe eczema in kids

NCT ID NCT05388760

Completed Disease control Sponsor: LEO Pharma Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a drug called tralokinumab in 28 children aged 6 to 12 with moderate-to-severe eczema. The goal was to see how the drug moves through the body and if it is safe. Children received injections over several weeks and used moisturizers daily. The trial is complete, but results are not yet public.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tralokinumab
What this could lead to: If successful, this could provide a new treatment option for children with moderate-to-severe eczema that is not well controlled by creams.
What could go wrong: This is a small, early-phase trial (Phase 2) with only 28 children, so results may not apply to all. The drug may cause side effects or not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS

Contacts and locations

Locations

LEO Pharma Investigational Site

Brno, 625 00, Czechia
LEO Pharma Investigational Site

Prague, 150 06, Czechia
LEO Pharma Investigational Site

Reims, Ardennes, 51100, France
LEO Pharma Investigational Site

Rotterdam, 3011 TG, Netherlands
LEO Pharma Investigational Site

Utrecht, 3584 CX, Netherlands
LEO Pharma Investigational Site

Cadiz, Andalusia, 11009, Spain
LEO Pharma Investigational Site

Esplugues de Llobregat, Barcelona, 08950, Spain
LEO Pharma Investigational Site

Alicante, 03010, Spain
LEO Pharma Investigational Site

Manchester, Greater Manchester, M13 9WL, United Kingdom
LEO Pharma Investigational Site

London, SE1 9RT, United Kingdom
LEO Pharma Investigational Site

Sheffield, S10 2TH, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.